Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus

被引:49
作者
Meeprasert, Arthitaya [1 ]
Hannongbua, Supot [1 ]
Rungrotmongkol, Thanyada [2 ]
机构
[1] Chulalongkorn Univ, Dept Chem, Fac Sci, Computat Chem Unit Cell, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Dept Biochem, Fac Sci, Bangkok 10330, Thailand
关键词
VITRO RESISTANCE PROFILE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; SIMULATIONS; REPLICATION; MECHANICS; MUTANTS; DESIGN;
D O I
10.1021/ci400605a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Hepatitis C virus (HCV) causes an infectious disease that manifests itself as liver inflammation, cirrhosis, and can lead to the development of liver cancer. Its NS3/4A serine protease is a potent target for drug design and development since it is responsible for cleavage of the scissile peptide bonds in the polyprotein important for the HCV life cycle. Herein, the ligand-target interactions and the binding free energy of the four current NS3/4A inhibitors (boceprevir, telaprevir, danoprevir, and BI201335) were investigated by all-atom molecular dynamics simulations with three different initial atomic velocities. The per-residue free energy decomposition suggests that the key residues involved in inhibitor binding were residues 41-43, 57, 81, 136-139, 155-159, and 168 in the NS3 domain. The van der Waals interactions yielded the main driving force for inhibitor binding at the protease active site for the cleavage reaction. In addition, the highest number of hydrogen bonds was formed at the reactive PI site of the four studied inhibitors. Although the hydrogen bond patterns of these inhibitors were different, their P3 site was most likely to be recognized by the A157 backbone. Both molecular mechanic (MM)/Poisson-Boltzmann surface area and MM/generalized Born surface area approaches predicted the relative binding affinities of the four inhibitors in a somewhat similar trend to their experimentally derived biological activities.
引用
收藏
页码:1208 / 1217
页数:10
相关论文
共 50 条
  • [1] An overview about hepatitis C: A devastating virus
    Bostan, Nazish
    Mahmood, Tariq
    [J]. CRITICAL REVIEWS IN MICROBIOLOGY, 2010, 36 (02) : 91 - 133
  • [2] The Amber biomolecular simulation programs
    Case, DA
    Cheatham, TE
    Darden, T
    Gohlke, H
    Luo, R
    Merz, KM
    Onufriev, A
    Simmerling, C
    Wang, B
    Woods, RJ
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) : 1668 - 1688
  • [3] Computer-assisted analysis of the interactions of macrocyclic inhibitors with wild type and mutant D168A hepatitis C virus NS3 serine protease
    da Cunha, EFF
    Ramalho, TC
    Taft, CA
    de Alencastro, RB
    [J]. LETTERS IN DRUG DESIGN & DISCOVERY, 2006, 3 (01) : 17 - 28
  • [4] De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149
  • [5] A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations
    Duan, Y
    Wu, C
    Chowdhury, S
    Lee, MC
    Xiong, GM
    Zhang, W
    Yang, R
    Cieplak, P
    Luo, R
    Lee, T
    Caldwell, J
    Wang, JM
    Kollman, P
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2003, 24 (16) : 1999 - 2012
  • [6] Durantel David, 2003, Expert Rev Anti Infect Ther, V1, P441, DOI 10.1586/14787210.1.3.441
  • [7] Current Therapies for Chronic Hepatitis C
    Ferguson, McKenzie C.
    [J]. PHARMACOTHERAPY, 2011, 31 (01): : 92 - 111
  • [8] Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus
    Frecer, V
    Kabelác, M
    De Nardi, P
    Pricl, S
    Miertus, S
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2004, 22 (03) : 209 - 220
  • [9] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
  • [10] Frisch M., 2004, GAUSSIAN 03 REVISION, DOI DOI 10.1016/J.MOLSTRUC.2017.03.014